Lumexa Imaging (NASDAQ:LMRI) Director Brett Brodnax Buys 35,000 Shares

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) Director Brett Brodnax bought 35,000 shares of the stock in a transaction dated Tuesday, May 19th. The stock was bought at an average price of $7.25 per share, for a total transaction of $253,750.00. Following the purchase, the director directly owned 62,027 shares of the company’s stock, valued at approximately $449,695.75. The trade was a 129.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Lumexa Imaging Trading Up 10.5%

LMRI stock traded up $0.78 during trading on Thursday, hitting $8.18. 940,684 shares of the company traded hands, compared to its average volume of 896,240. The stock’s 50-day moving average is $9.87. Lumexa Imaging Holdings, Inc. has a 1 year low of $6.45 and a 1 year high of $19.45.

Institutional Investors Weigh In On Lumexa Imaging

A number of hedge funds and other institutional investors have recently made changes to their positions in LMRI. Assetmark Inc. acquired a new stake in shares of Lumexa Imaging during the 4th quarter worth approximately $36,000. Strs Ohio acquired a new stake in Lumexa Imaging in the 1st quarter valued at $38,000. PNC Financial Services Group Inc. acquired a new stake in Lumexa Imaging in the 1st quarter valued at $63,000. State of Wyoming acquired a new stake in Lumexa Imaging in the 1st quarter valued at $91,000. Finally, Barclays PLC acquired a new stake in Lumexa Imaging in the 4th quarter valued at $133,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LMRI. Weiss Ratings began coverage on shares of Lumexa Imaging in a research note on Wednesday, May 13th. They set a “sell (e-)” rating on the stock. Barclays dropped their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Raymond James Financial raised shares of Lumexa Imaging from an “outperform” rating to a “strong-buy” rating and set a $23.00 price objective on the stock in a research note on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).